Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCP-Tacro vs Prograf in De Novo Kidney Transplant
NCT00765661Phase 2Completed
- Sponsor
- Veloxis Pharmaceuticals
- Start
- Sep 2008
- Primary completion
- Feb 2010
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Envarsus XR in kidney transplant rejection (2 arms), sponsored by Veloxis Pharmaceuticals. Primary endpoint: Pharmacokinetics of LCP-Tacro™ Tablets in the First 14 Days After Transplantation. Started Sep 2008; status: completed.
02
Drugs
Envarsus XR
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00765661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00765661.